|
Keywords
|
field-effect transistor, graphdiyne, bioaffinity assay, aptasensor, DNA sequence, CA19-9, CA15-3, microRNA-155, COVID-19
|
|
Abstract
|
Graphdiyne’s (GDY’s) outstanding features have made it a novel 2D nanomaterial and a great candidate for electronic gadgets and optoelectronic devices, and it has opened new opportunities for the development of highly sensitive electronic and optical detection methods as well. Here, we testified a non-covalent grafting strategy in which GDY serves as a charge carrier layer and a bioaffinity substrate to immobilize biological receptors on GDY-based field-effect transistor (FET) devices. Firm non-covalent anchoring of biological molecules via pyrene groups and electrostatic interactions in addition to preserved electrical properties of GDY endows it with features of an ultrasensitive and stable detection mechanism. With emerging new forms and extending the subtypes of the already existing fatal diseases, genetic and biological knowledge demands more details. In this regard, we constructed simple yet efficient platforms using GDY-based FET devices in order to detect different kinds of biological molecules that threaten human health. The resulted data showed that the proposed non-covalent bioaffinity assays in GDY-based FET devices could be considered reliable strategies for novel label-free biosensing platforms, which still reach a high on/off ratio of over 104. The limits of detection of the FET devices to detect DNA strands, the CA19-9 antigen, microRNA-155, the CA15-3 antigen, and the COVID-19 antigen were 0.2 aM, 0.04 pU mL−1, 0.11 aM, 0.043 pU mL−1, and 0.003 fg mL−1, respectively, in the linear ranges of 1 aM to 1 pM, 1 pU mL−1 to 0.1 μU mL−1, 1 aM to 1 pM, 1 pU mL−1 to 10 μU mL−1, and 1 fg mL−1 to 10 ng mL−1, respectively. Finally, the extraordinary performance of these label-free FET biosensors with low detection limits, high sensitivity and selectivity, capable of being miniaturized, and implantability for in vivo analysis makes them a great candidate in disease diagnostics and pointof-care testing.
|